ORZORA: OPEN-LABEL PHASE IV TRIAL OF OLAPARIB IN PATIENTS WITH BRCA-MUTATED OVARIAN CANCER

被引：0
|
作者：
Pignata, S. [1 ]
Lewis, J. [2 ]
Tchakov, I. [2 ]
Robertson, J. D. [3 ]
Morris, T. [3 ]
Jayawardene, D. [4 ]
Tyczynski, J. E. [4 ]
Hodgson, D. R. [3 ]
Mills, J. [3 ]
Di Maio, M. [5 ]
机构：
[1] Natl Canc Inst Naples, Urogynecol Dept, Naples, Italy
[2] AstraZeneca, Global Med Affairs, Cambridge, England
[3] AstraZeneca, Global Clin Dev, Macclesfield, Cheshire, England
[4] AstraZeneca, Global Medicines Dev, Gaithersburg, MD USA
[5] Univ Turin, Dept Oncol, Turin, Italy
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2015年 / 25卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ESGO-0933
引用
收藏
页码：1469 / 1470
页数：2
相关论文
共 50 条
  • [11] Progress in BRCA-Mutated Ovarian Cancer
    Spriggs, David R.
    Longo, Dan L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (26): : 2567 - 2568
  • [12] Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy
    Lorusso, Domenica
    Tripodi, Elisa
    Maltese, Giuseppa
    Lepori, Stefano
    Sabatucci, Ilaria
    Bogani, Giorgio
    Raspagliesi, Francesco
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 1501 - 1509
  • [13] Late Breaking Abstract An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed (PSR) ovarian cancer (OC)
    Drew, Y.
    de Jonge, M.
    Hong, S. H.
    Park, Y. H.
    Wolfer, A.
    Brown, J.
    Ferguson, M.
    Gore, M. E.
    Alvarez, R. H.
    Gresty, C.
    Angell, H.
    Meyer, K.
    Learoyd, M.
    Tang, M.
    Lanasa, M.
    Herbolsheimer, P.
    Domchek, S. M.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 246 - 247
  • [14] Maintenance olaparib in Asian patients with germline BRCA-mutated metastatic pancreatic cancer
    Oh, Do-Youn
    Park, Joon Oh
    Kindler, Hedy L.
    Hammel, Pascal
    Reni, Michele
    Van Cutsem, Eric
    Macarulla, Teresa
    Hall, Michael J.
    Arnold, Dirk
    Reinacker-Schick, Anke
    Tortora, Giampaolo
    Algul, Hana
    O'Reilly, Eileen M.
    McGuiness, David
    Liu, Yu-Zhen
    Cui, Karen
    Schlienger, Katia
    Locker, Gershon Y.
    Golan, Talia
    ANNALS OF ONCOLOGY, 2021, 32 : S319 - S319
  • [15] Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer REPLY
    Robson, Mark
    Goessl, Carsten
    Domchek, Susan
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (18): : 1792 - 1793
  • [16] Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
    Golan, Talia
    Hammel, Pascal
    Reni, Michele
    Van Cutsem, Eric
    Macarulla, Teresa
    Hall, Michael J.
    Park, Joon-Oh
    Hochhauser, Daniel
    Arnold, Dirk
    Oh, Do-Youn
    Reinacher-Schick, Anke
    Tortora, Giampaolo
    Alguel, Hana
    O'Reilly, Eileen M.
    McGuinness, David
    Cui, Karen Y.
    Schlienger, Katia
    Locker, Gershon Y.
    Kindler, Hedy L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (04): : 317 - 327
  • [17] Real-world experience of olaparib as maintenance therapy in BRCA-mutated recurrent ovarian cancer
    Angela Cho
    Jeong-Yeol Park
    Shin-Wha Lee
    Dae-Yeon Kim
    Dae-Shik Suh
    Jong-Hyeok Kim
    Yong-Man Kim
    Young-Tak Kim
    Archives of Gynecology and Obstetrics, 2021, 304 : 1055 - 1063
  • [18] Real-world experience of olaparib as maintenance therapy in BRCA-mutated recurrent ovarian cancer
    Cho, Angela
    Park, Jeong-Yeol
    Lee, Shin-Wha
    Kim, Dae-Yeon
    Suh, Dae-Shik
    Kim, Jong-Hyeok
    Kim, Yong-Man
    Kim, Young-Tak
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2021, 304 (04) : 1055 - 1063
  • [19] Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial
    Lorusso, D.
    Scambia, G.
    Pignata, S.
    Sorio, R.
    Amadio, G.
    Lepori, S.
    Mosconi, A.
    Pisano, C.
    Mangili, G.
    Maltese, G.
    Sabbatini, R.
    Artioli, G.
    Gamucci, T.
    Di Napoli, M.
    Capoluongo, E.
    Ludovini, V.
    Raspagliesi, F.
    Ferrandina, G.
    ANNALS OF ONCOLOGY, 2016, 27 (03) : 487 - 493
  • [20] An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC)
    Domchek, Susan M.
    Postel-Vinay, Sophie
    Bang, Yung-Jue
    Park, Yeonh H.
    Alexandre, Jerome
    Delord, Jean-Pierre
    Italiano, Antoine
    You, Benoit
    Bastian, Sara
    Krebs, Matthew
    Wang, Ding
    Waqar, Saiama
    Angell, Helen
    Learoyd, Maria
    Chang, Shao-Chun
    Gresty, Christopher
    Herbolsheimer, Pia
    Kaufman, Bella
    CANCER RESEARCH, 2018, 78 (04)
12345